Should radioiodine now be first line treatment for Graves’ disease?

BACKGROUND: Radioiodine represents a cost-effective treatment option for Graves’ disease. In the UK, it is traditionally reserved for patients who relapse after initial thionamide therapy. In a change from current practice, the new guidelines of the National Institute for Health and Care Excellence...

Descripción completa

Detalles Bibliográficos
Autores principales: Okosieme, Onyebuchi E., Taylor, Peter N., Dayan, Colin M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7061474/
https://www.ncbi.nlm.nih.gov/pubmed/32165924
http://dx.doi.org/10.1186/s13044-020-00077-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7061474/
https://www.ncbi.nlm.nih.gov/pubmed/32165924
http://dx.doi.org/10.1186/s13044-020-00077-8

Ejemplares similares